回盛生物(300871) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was CNY 313,499,906.84, representing a 132.22% increase compared to CNY 135,002,023.52 in the same period last year[8]. - The net profit attributable to shareholders for Q1 2021 was CNY 63,457,333.99, a 150.59% increase from CNY 25,323,579.17 year-on-year[8]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 61,542,373.26, up 145.68% from CNY 25,049,336.92 in the previous year[8]. - The basic earnings per share for Q1 2021 was CNY 0.57, an increase of 83.87% compared to CNY 0.31 in the same period last year[8]. - The total operating revenue for the first quarter of 2021 was CNY 313,499,906.84, a significant increase from CNY 135,002,023.52 in the same period last year, representing a growth of approximately 132.5%[55]. - Net profit attributable to shareholders reached CNY 63,457,333.99, reflecting a growth of 150.59% compared to the same period last year[24]. - Basic earnings per share increased to CNY 0.57, up 83.87% year-on-year[24]. - Operating profit rose to CNY 73,631,806.44, marking a 149.62% increase from the previous year[24]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,788,363,688.87, a 2.06% increase from CNY 1,752,225,832.51 at the end of the previous year[8]. - The net assets attributable to shareholders at the end of the reporting period were CNY 1,442,607,448.49, reflecting a 4.60% increase from CNY 1,379,150,114.50 at the end of the previous year[8]. - The total liabilities decreased to CNY 345,756,240.38 from CNY 373,075,718.01, indicating a reduction of approximately 7.3%[49]. - The company's total assets as of March 31, 2021, amounted to CNY 1,788,363,688.87, compared to CNY 1,752,225,832.51 at the end of 2020, reflecting an increase of about 2.1%[50]. - The total equity attributable to the parent company increased to CNY 1,442,607,448.49 from CNY 1,379,150,114.50, representing a growth of about 4.6%[50]. Cash Flow - The net cash flow from operating activities for Q1 2021 was negative CNY 20,061,570.80, a decrease of 277.76% compared to a positive CNY 11,285,760.37 in the same period last year[8]. - The cash and cash equivalents increased to CNY 465,240,761.42 as of March 31, 2021, compared to CNY 345,343,353.84 at the end of 2020[47]. - The cash inflow from investment activities included 410,000,000.00 from recovering investments, indicating strong investment recovery efforts[67]. - The total cash inflow from investment activities was 411,485,219.59, with a net cash flow of 152,360,259.27, a substantial improvement from -26,380,284.17 in the previous period[64]. - The cash flow from operating activities showed a total inflow of 305,652,169.46, compared to 128,494,196.22 in the prior period, indicating improved revenue generation[63]. Research and Development - Research and development expenses increased by 62.28% to CNY 5,914,988.69, indicating a focus on innovation[20]. - The company has signed three clinical contracts and is on track with its research projects, having introduced six new R&D personnel[30]. - The company obtained registration certificates for two new veterinary drugs, enhancing its market competitiveness and supporting the integration of raw material and formulation strategies[27]. Operational Challenges and Risks - The company faces risks from ongoing pandemic impacts, commodity price fluctuations, and potential credit risks from large-scale breeding group clients[31]. - The company has maintained a diversified customer base, with no significant reliance on any single customer, mitigating operational risks[28]. - The company experienced a credit impairment loss of CNY 1.68 million, compared to CNY 1.45 million in the previous year, indicating a slight increase in credit risk[56]. Investments and Projects - The company has invested a total of 85,071.25 million yuan in fundraising, with 15,293.18 million yuan utilized in the current quarter[34]. - The new automated production base project at Xingu Base has achieved a 63.01% investment progress, while the R&D and quality inspection center project has reached 69.10%[34]. - The company has completed the construction of its traditional Chinese medicine extraction workshop, which is now at the GMP acceptance stage[30]. - The company has invested CNY 26,071.25 million in the annual production project of 1,000 tons of Tylosin, with a project progress of 27.82% and expected completion by the end of 2021[37]. - The total investment for the Tylosin project is CNY 38,000 million, with CNY 7,251.73 million raised from public offerings[37]. Financial Adjustments and Standards - The company adopted new leasing standards effective January 1, 2021, impacting financial statement adjustments[76]. - The first quarter report was not audited, which may affect the reliability of the financial data presented[76].